{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:36:45Z","timestamp":1777592205700,"version":"3.51.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:00:00Z","timestamp":1740182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2022-2Z-20215"],"award-info":[{"award-number":["2022-2Z-20215"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2022-2Z-20215"],"award-info":[{"award-number":["2022-2Z-20215"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2022-2Z-20215"],"award-info":[{"award-number":["2022-2Z-20215"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2022-2Z-20215"],"award-info":[{"award-number":["2022-2Z-20215"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2022-2Z-20215"],"award-info":[{"award-number":["2022-2Z-20215"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2022-2Z-20215"],"award-info":[{"award-number":["2022-2Z-20215"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Chemistry"],"DOI":"10.1186\/s13065-025-01424-2","type":"journal-article","created":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T21:40:17Z","timestamp":1740260417000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Development of a novel UHPLC-MS\/MS method for quantitative analysis of pirtobrutinib in rat plasma: application to pharmacokinetic study"],"prefix":"10.1186","volume":"19","author":[{"given":"Meijuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangshuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruihua","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,22]]},"reference":[{"issue":"9","key":"1424_CR1","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00262-021-02908-5","volume":"70","author":"L Good","year":"2021","unstructured":"Good L, Benner B, Carson WE. Bruton\u2019s tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment. Cancer Immunol Immunother. 2021;70(9):2439\u201351.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1424_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.","journal-title":"Mol Cancer"},{"key":"1424_CR3","doi-asserted-by":"crossref","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P. Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia. 202;35(2):312\u201332.","DOI":"10.1038\/s41375-020-01072-6"},{"key":"1424_CR4","unstructured":"NCCN Guidelines Version 1. 2023 Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. https:\/\/www.nccn.org\/"},{"issue":"6","key":"1424_CR5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","volume":"25","author":"JA Burger","year":"2019","unstructured":"Burger JA. Bruton tyrosine kinase inhibitors: Present and Future. Cancer J. 2019;25(6):386\u201393.","journal-title":"Cancer J"},{"issue":"10","key":"1424_CR6","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.clml.2023.07.011","volume":"23","author":"S Easaw","year":"2023","unstructured":"Easaw S, Ezzati S, Coombs CC. SOHO State of the art updates and next questions: updates on BTK inhibitors for the treatment of chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2023;23(10):697\u2013704.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"1424_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3390\/jpm11080764","volume":"11","author":"KL Lewis","year":"2021","unstructured":"Lewis KL, Cheah CY, Non-Covalent BTK. Inhibitors-the New BTKids on the Block for B-Cell malignancies. J Pers Med. 2021;11(8):764.","journal-title":"J Pers Med"},{"issue":"14","key":"1424_CR8","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.3390\/cancers15143648","volume":"15","author":"S Montoya","year":"2023","unstructured":"Montoya S, Thompson MC. Non-covalent Bruton\u2019s tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Cancers (Basel). 2023;15(14):3648.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1424_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/1078-0432.CCR-23-1272","volume":"30","author":"D Telaraja","year":"2024","unstructured":"Telaraja D, Kasamon YL, Collazo JS, Leong R, Wang K, Li P, Dahmane E, Yang Y, Earp J, Grimstein M, Rodriguez LR, Theoret MR, Gormley NJ. FDA approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma. Clin Cancer Res. 2024;30(1):17\u201322.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1424_CR10","first-page":"62","volume":"142","author":"EB Gomez","year":"2023","unstructured":"Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, Hanson LM, Brown NE, Gong X, Stephens J, Wu W, Lippincott I, Ku KS, Walgren RA, Abada PB, Ballard JA, Allerston CK, Brandhuber BJ. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023;142(1):62\u201372.","journal-title":"Blood"},{"issue":"10277","key":"1424_CR11","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","volume":"397","author":"AR Mato","year":"2021","unstructured":"Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Abdel-Wahab O, Schuster SJ, Palomba ML, Lewis KL, Roeker LE, Davids MS, Tan XN, Fenske TS, Wallin J, Tsai DE, Ku NC, Zhu E, Chen J, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study. Lancet. 2021;397(10277):892\u2013901.","journal-title":"Lancet"},{"issue":"6","key":"1424_CR12","first-page":"1866","volume":"109","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Jen MH, Hess LM, Zhang J, Goebel B, Pagel JM, Abhyankar S, Davids MS, Eyre TA. Pirtobrutinib versus Venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison. Haematologica. 2024;109(6):1866\u201373.","journal-title":"Haematologica"},{"key":"1424_CR13","unstructured":"Food and Drug Administration. Bioanalytical Method Validation Guidance for Industry. 2018. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry"},{"key":"1424_CR14","doi-asserted-by":"crossref","unstructured":"Rathod RH, Chaudhari SR, Patil AS, Shirkhedkar AA. Ultra-high performance liquid chromatography-MS\/MS (UHPLC-MS\/MS) in practice: analysis of drugs and pharmaceutical formulations. Futur J Pharm Sci. 2019, 5(6).","DOI":"10.1186\/s43094-019-0007-8"}],"container-title":["BMC Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01424-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13065-025-01424-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13065-025-01424-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T21:40:22Z","timestamp":1740260422000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcchem.biomedcentral.com\/articles\/10.1186\/s13065-025-01424-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,22]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1424"],"URL":"https:\/\/doi.org\/10.1186\/s13065-025-01424-2","relation":{},"ISSN":["2661-801X"],"issn-type":[{"value":"2661-801X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,22]]},"assertion":[{"value":"31 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"According to the Guidelines of the Experimental Animal Care and Use of Laboratory Animals of The Beijing Friendship Hospital. All animal procedures and experimental protocols were approved by Institutional Animal Care and Use Committee of Beijing Friendship Hospital, Capital Medical University (Ethics approval number: 24-1003).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"50"}}